To date, one must conclude that the pace of progress in disease control and preservation of functional integrity and quality of life for pediatric brain tumors remains below that of most other major types of childhood cancers. Recent advances in cellular and molecular biology have further characterized some of the more common pediatric brain tumor histiotypes - identifying molecular targets against which therapeutic strategies are now being developed. Thus, the scientific opportunities for advancing treatment options for childhood brain tumors have expanded considerably since the inception of the Pediatric Brain Tumor Consortium (PBTC) in April 1999, as the molecular characteristics of childhood brain cancers are understood far better today. These advances are paralleled by an expansion in the number and variety of anticancer agents targeted towards specific signaling pathways that control growth and proliferation of cancer cells. The combination of both factors, increased understanding of cancer biology and availability of novel therapeutic strategies, creates clinical research opportunities for the PBTC to continue to exploit. The mission of the PBTC is to contribute rapidly and effectively to the understanding and cure of pediatric CNS tumors taking advantage of recent advances in cellular and molecular biology by using these findings to drive the conduct of multi-center, multidisciplinary innovative studies with designs and analyses based on uniformly high-quality statistical science. While the primary mission of the PBTC is to identify, through laboratory and clinical science, superior treatment strategies for children with brain cancers, the PBTC investigators recognize their profound responsibility to meet the special needs of the children and families as they face this enormous challenge and will address these needs with focused quality of life research. Members are also committed to working within their institutions and communities to improve support services and follow-up care for these patients and their families.

Public Health Relevance

Brain tumors represent 20% of all childhood cancers;approximately 2700 children and adolescents presenting with CNS tumors annually in the U.S. A significant proportion has aggressive, malignant histiotypes typically with 5-year survival rates of less than 10-25%. The current treatment options for children with brain tumors result in suboptimal functional outcomes and a substantial proportion of children with brain cancers who do survive exhibit functional impediments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (J1))
Program Officer
Smith, Malcolm M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Wu, Jianrong (2015) Power and sample size for randomized phase III survival trials under the Weibull model. J Biopharm Stat 25:16-28
Mulkern, Robert V; Ricci, Kelsey I; Vajapeyam, Sridhar et al. (2015) Pediatric brain tumor consortium multisite assessment of apparent diffusion coefficient z-axis variation assessed with an ice-water phantom. Acad Radiol 22:363-9
Wu, Jianrong; Xiong, Xiaoping (2015) Group Sequential Design for Randomized Phase III Trials under the Weibull Model. J Biopharm Stat 25:1190-205
Zukotynski, Katherine; Fahey, Frederic; Kocak, Mehmet et al. (2014) 18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium. J Nucl Med 55:1473-80
Gururangan, Sridharan; Fangusaro, Jason; Poussaint, Tina Young et al. (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol 16:310-7
Zukotynski, Katherine A; Fahey, Frederic H; Vajapeyam, Sridhar et al. (2013) Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 54:1237-43
Fangusaro, Jason; Gururangan, Sridharan; Poussaint, Tina Young et al. (2013) Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer 119:4180-7
Kilburn, Lindsay B; Kocak, Mehmet; Schaedeli Stark, Franziska et al. (2013) Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol 15:759-66
Fouladi, Maryam; Stewart, Clinton F; Blaney, Susan M et al. (2013) A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol 114:173-9
Warren, Katherine E; Gururangan, Sri; Geyer, J Russell et al. (2012) A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol 106:643-9

Showing the most recent 10 out of 45 publications